Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$63.74 USD

63.74
9,888,884

+1.37 (2.20%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $63.73 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for EW

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Edwards Lifesciences Corporation falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 1,645 1,215 1,467 1,403 1,517
Receivables 837 699 665 603 599
Notes Receivable 0 0 0 0 0
Inventories 1,168 876 727 802 641
Other Current Assets 386 306 322 283 227
Total Current Assets 4,036 3,096 3,181 3,091 2,984
Net Property & Equipment 1,749 1,633 1,547 1,395 1,060
Investments & Advances 584 1,239 1,834 802 0
Other Non-Current Assets 0 0 0 0 586
Deferred Charges 755 484 247 231 172
Intangibles 1,682 1,450 1,492 1,505 1,504
Deposits & Other Assets 464 299 111 120 102
Total Assets 9,363 8,293 8,503 7,237 6,488
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 201 202 205 197 180
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 969 795 802 670 697
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 1,195 1,022 1,032 894 902
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 597 596 596 595 594
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 778 798 970 1,101 784
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,644 2,486 2,667 2,663 2,340
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 651 646 642 636 218
Capital Surplus 2,274 1,969 1,700 1,438 1,623
Retained Earnings 8,992 7,590 6,068 4,565 3,742
Other Equity -173 -255 -158 -161 -156
Treasury Stock 5,025 4,144 2,417 1,904 1,279
Total Shareholder's Equity 6,719 5,807 5,836 4,574 4,148
Total Liabilities & Shareholder's Equity 9,363 8,293 8,503 7,237 6,488
Total Common Equity 6,719 5,807 5,836 4,574 4,148
Shares Outstanding 606.50 618.20 624.30 623.20 625.70
Book Value Per Share 11.08 9.39 9.35 7.34 6.63

Fiscal Year End for Edwards Lifesciences Corporation falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 1,990 1,698 1,645 1,864 1,509
Receivables 834 877 837 802 817
Notes Receivable NA 0 0 0 0
Inventories 1,025 1,207 1,168 1,032 980
Other Current Assets 667 389 386 369 341
Total Current Assets 4,516 4,171 4,036 4,068 3,647
Net Property & Equipment 1,640 1,768 1,749 1,681 1,662
Investments & Advances 353 456 584 705 856
Other Non-Current Assets 307 0 0 0 0
Deferred Charges 833 777 755 652 611
Intangibles 1,568 1,700 1,682 1,727 1,731
Deposits & Other Assets 790 768 464 447 412
Total Assets 10,099 9,736 9,363 9,371 9,004
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable 1,088 212 201 191 193
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 874 969 1,024 940
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities 107 0 0 0 0
Total Current Liabilities 1,217 1,111 1,195 1,239 1,157
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt 597 597 597 597 597
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities 706 778 738 740
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities 2,595 2,550 2,644 2,644 2,558
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) 654 652 651 650 649
Capital Surplus 2,476 2,380 2,274 2,211 2,146
Retained Earnings 9,711 9,344 8,992 8,623 8,238
Other Equity -153 -165 -173 -181 -185
Treasury Stock 5,183 5,025 5,025 4,576 4,401
Total Shareholder's Equity 7,505 7,186 6,719 6,727 6,447
Total Liabilities & Shareholder's Equity 10,099 9,736 9,363 9,371 9,004
Total Common Equity 107,504 7,186 6,719 6,727 6,447
Shares Outstanding 602.60 602.60 606.50 606.50 607.90
Book Value Per Share 178.40 11.93 11.08 11.09 10.60